JD 010
Alternative Names: JD-010Latest Information Update: 13 Jan 2023
At a glance
- Originator Beijing JD Biotech
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haematological malignancies
Most Recent Events
- 01 Dec 2022 Phase-I clinical trials in B-cell Haematologic malignancies(Second-line therapy or greater) in China (Parenteral) (NCT05645601 )
- 30 Nov 2022 Preclinical trials in Haematologic malignancies in China (Parenteral), prior to December 2022